The potent activity of type-II inhibitors against JAK2 p. V617F-mutant hematopoietic cells suggests that they may be a more effective than type-I JAK inhibitors for the treatment of JAK2-altered ALL. Here, JAK2 is linked to acute lymphoblastic leukemia.